An experimental treatment for Huntington disease failed a late-stage trial, Medivation Inc. said Monday.
The San Francisco biotech company (NASDAQ: MDVN) and partner Pfizer Inc. (NYSE: PFE) said the drug, Dimebon, failed to hit its two main goals in the 403-patient Phase III study. It is the second strike against Dimebon, a drug that two years ago failed a late-stage trial in Alzheimer’s disease.
Medivation CEO David Hung said the company will stop its Dimebon trial in Huntington disease. It is continuing its Phase III trial of Dimebon in Alzheimer's patients.